Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2018 Apr 3

PMID 29606986

Citations 6

Authors

Karolina Marek-Bukowiec

Andrzej Konieczny

Krzysztof Ratajczyk

Wojciech Witkiewicz

Affiliations

Soon will be listed here.

Abstract

Early detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge. Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis. It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would improve the clinical care and outcome of patients suffering from IgAN. This review summarises the findings from previous mass spectrometry- (MS-) based studies dedicated to the discovery of urinary peptide profiles specific to IgAN. There is a substantial number of urinary peptides that have been discovered to date, which show promise as biomarkers of IgAN; however, all of them require further, rigorous validation in well-planned studies, involving a large number of subjects who represent diverse and numerous populations.

Citing Articles

IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.

Du Y, Cheng T, Liu C, Zhu T, Guo C, Li S Diagnostics (Basel). 2023; 13(2).

PMID: 36673113 PMC: 9857562. DOI: 10.3390/diagnostics13020303.

The Feasibility of Targeted Magnetic Iron Oxide Nanoagent for Noninvasive IgA Nephropathy Diagnosis.

Wu Y, Huang Q, Wang J, Dai Y, Xiao M, Li Y Front Bioeng Biotechnol. 2021; 9:755692.

PMID: 34900958 PMC: 8656216. DOI: 10.3389/fbioe.2021.755692.

Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy.

Hayashi R, Ueno Y, Tanaka S, Onishi K, Takasago T, Wakai M Intest Res. 2020; 19(4):430-437.

PMID: 33153254 PMC: 8566828. DOI: 10.5217/ir.2020.00067.

Differential expression of peptides serves as an indicator of IgA nephropathy in pediatric patients.

Rao C, Yang F, Lai Z, Chen S, Lu X, Jiang X Exp Ther Med. 2020; 20(5):67.

PMID: 32963597 PMC: 7490786. DOI: 10.3892/etm.2020.9195.

Formalin-fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy.

Cox S, Chiurlia S, Divella C, Rossini M, Serino G, Bonomini M Sci Rep. 2020; 10(1):15164.

PMID: 32938960 PMC: 7494931. DOI: 10.1038/s41598-020-72026-2.

References

Mischak H, Julian B, Novak J . High-resolution proteome/peptidome analysis of peptides and low-molecular-weight proteins in urine. Proteomics Clin Appl. 2010; 1(8):792. PMC: 2811330. DOI: 10.1002/prca.200700043. View

Rose C, Parker A, Jefferson B, Cartmell E . The Characterization of Feces and Urine: A Review of the Literature to Inform Advanced Treatment Technology. Crit Rev Environ Sci Technol. 2015; 45(17):1827-1879. PMC: 4500995. DOI: 10.1080/10643389.2014.1000761. View

Toledo K, Perez M, Espinosa M, Gomez J, Lopez M, Redondo D . [Complications associated with percutaneous renal biopsy in Spain, 50 years later]. Nefrologia. 2010; 30(5):539-43. DOI: 10.3265/Nefrologia.pre2010.Jul.10404. View

Smith E, Zurakowski D, Saad A, Scott R, Moses M . Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008; 14(8):2378-86. DOI: 10.1158/1078-0432.CCR-07-1253. View

Stratta P, Canavese C, Marengo M, Mesiano P, Besso L, Quaglia M . Risk management of renal biopsy: 1387 cases over 30 years in a single centre. Eur J Clin Invest. 2007; 37(12):954-63. DOI: 10.1111/j.1365-2362.2007.01885.x. View

Reid S, Cawthon P, Craig J, Samuels J, Molony D, Strippoli G . Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011; (3):CD003962. DOI: 10.1002/14651858.CD003962.pub2. View

Julian B, Wittke S, Haubitz M, Zurbig P, Schiffer E, McGuire B . Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J Urol. 2007; 25(5):467-76. DOI: 10.1007/s00345-007-0192-5. View

Sigdel T, Nicora C, Hsieh S, Dai H, Qian W, Camp 2nd D . Optimization for peptide sample preparation for urine peptidomics. Clin Proteomics. 2014; 11(1):7. PMC: 3944950. DOI: 10.1186/1559-0275-11-7. View

Wiesner C, Hannum C, Reckamp K, Figlin R, DuBridge R, Mimi Roy S . Consistency of a two clinical site sample collection: a proteomics study. Proteomics Clin Appl. 2010; 4(8-9):726-38. DOI: 10.1002/prca.200900206. View

10.

Bellur S, Troyanov S, Cook H, Roberts I . Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant. 2011; 26(8):2533-6. DOI: 10.1093/ndt/gfq812. View

11.

Theodorescu D, Wittke S, Ross M, Walden M, Conaway M, Just I . Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006; 7(3):230-40. DOI: 10.1016/S1470-2045(06)70584-8. View

12.

Beltrami C, Clayton A, Phillips A, Fraser D, Bowen T . Analysis of urinary microRNAs in chronic kidney disease. Biochem Soc Trans. 2012; 40(4):875-9. DOI: 10.1042/BST20120090. View

13.

Schaub S, Wilkins J, Antonovici M, Krokhin O, Weiler T, Rush D . Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant. 2005; 5(4 Pt 1):729-38. DOI: 10.1111/j.1600-6143.2005.00766.x. View

14.

Hession C, Decker J, Sherblom A, Kumar S, Yue C, Mattaliano R . Uromodulin (Tamm-Horsfall glycoprotein): a renal ligand for lymphokines. Science. 1987; 237(4821):1479-84. DOI: 10.1126/science.3498215. View

15.

Schley G, Koberle C, Manuilova E, Rutz S, Forster C, Weyand M . Comparison of Plasma and Urine Biomarker Performance in Acute Kidney Injury. PLoS One. 2015; 10(12):e0145042. PMC: 4682932. DOI: 10.1371/journal.pone.0145042. View

16.

Sinniah R . Occurrence of mesangial IgA and IgM deposits in a control necropsy population. J Clin Pathol. 1983; 36(3):276-9. PMC: 498197. DOI: 10.1136/jcp.36.3.276. View

17.

Wilhelm M, Schlegl J, Hahne H, Gholami A, Lieberenz M, Savitski M . Mass-spectrometry-based draft of the human proteome. Nature. 2014; 509(7502):582-7. DOI: 10.1038/nature13319. View

18.

Zhu M, Chen J, Xu A . Factors that can minimize bleeding complications after renal biopsy. Int Urol Nephrol. 2014; 46(10):1969-75. PMC: 4176568. DOI: 10.1007/s11255-013-0560-6. View

19.

Nagaraj N, Mann M . Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J Proteome Res. 2010; 10(2):637-45. DOI: 10.1021/pr100835s. View

20.

Haubitz M, Wittke S, Weissinger E, Walden M, Rupprecht H, Floege J . Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005; 67(6):2313-20. DOI: 10.1111/j.1523-1755.2005.00335.x. View